HARBIN GLORIA PHARMACEUTICALS Co., LTD (SHE:002437)
China · Delayed Price · Currency is CNY 2.930
-0.110 (-3.62%)
Nov 13, 2026, 3:04 PM CST
SHE:002437 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,893 | 2,131 | 2,436 | 2,619 | 3,103 | 3,131 |
Other Revenue | 4.38 | 4.38 | 5.02 | 7.02 | 5.09 | 14.07 |
| 1,897 | 2,135 | 2,441 | 2,626 | 3,108 | 3,145 | |
Revenue Growth | -15.61% | -12.51% | -7.06% | -15.51% | -1.19% | 2.96% |
Cost of Revenue | 1,038 | 1,169 | 1,137 | 1,096 | 1,362 | 832.93 |
Gross Profit | 859.79 | 966.36 | 1,303 | 1,530 | 1,746 | 2,312 |
Selling, General & Admin | 489.21 | 628.09 | 959.35 | 1,244 | 1,518 | 2,058 |
Research & Development | 84.45 | 78.43 | 90.79 | 85.44 | 100.63 | 97.73 |
Other Operating Expenses | 51.28 | 28.97 | 28.28 | 29.22 | 41.52 | 41.17 |
Operating Expenses | 624.77 | 735.59 | 1,078 | 1,358 | 1,660 | 2,197 |
Operating Income | 235.02 | 230.77 | 225.32 | 171.96 | 85.61 | 115.68 |
Interest Expense | -2.82 | -2.48 | -9.82 | -42.65 | -68.67 | -71.48 |
Interest & Investment Income | 143.92 | 141.62 | 15.21 | 18.47 | 20.78 | 17.21 |
Currency Exchange Gain (Loss) | -1.74 | -1.74 | 1.13 | 1.19 | 13.54 | -3.86 |
Other Non Operating Income (Expenses) | -4.87 | -0.41 | 0.81 | -6.47 | -4.19 | -14.1 |
EBT Excluding Unusual Items | 369.51 | 367.76 | 232.66 | 142.49 | 47.08 | 43.44 |
Impairment of Goodwill | - | - | - | - | -42.13 | - |
Gain (Loss) on Sale of Investments | -12.34 | 5.98 | -13.98 | -41.37 | -269.57 | -9.31 |
Gain (Loss) on Sale of Assets | 12.47 | 3.54 | 3.4 | 2.84 | 3.82 | 4.65 |
Asset Writedown | -8.6 | -8.88 | -3.53 | -0.28 | -37.32 | -1.84 |
Other Unusual Items | 59.07 | 41.22 | 65.15 | 71.08 | 27.44 | 49.03 |
Pretax Income | 420.1 | 409.62 | 283.69 | 176.78 | -269.68 | 85.97 |
Income Tax Expense | 33.95 | 27.26 | 41.15 | 48.08 | 19.84 | 32.14 |
Earnings From Continuing Operations | 386.15 | 382.36 | 242.54 | 128.7 | -289.52 | 53.84 |
Minority Interest in Earnings | -4.87 | -5.45 | -9.78 | -8.37 | -1.81 | -8.8 |
Net Income | 381.29 | 376.91 | 232.76 | 120.33 | -291.33 | 45.04 |
Net Income to Common | 381.29 | 376.91 | 232.76 | 120.33 | -291.33 | 45.04 |
Net Income Growth | 30.12% | 61.93% | 93.43% | - | - | -88.74% |
Shares Outstanding (Basic) | 2,198 | 2,193 | 2,198 | 2,200 | 2,199 | 2,197 |
Shares Outstanding (Diluted) | 2,223 | 2,235 | 2,262 | 2,200 | 2,199 | 2,197 |
Shares Change | -3.45% | -1.17% | 2.82% | 0.05% | 0.07% | -0.04% |
EPS (Basic) | 0.17 | 0.17 | 0.11 | 0.05 | -0.13 | 0.02 |
EPS (Diluted) | 0.17 | 0.17 | 0.10 | 0.05 | -0.13 | 0.02 |
EPS Growth | 34.77% | 63.85% | 88.12% | - | - | -88.74% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | 228.85 | 249.54 | 348.04 | 244.55 | 228.6 | 239.67 |
Free Cash Flow Per Share | 0.10 | 0.11 | 0.15 | 0.11 | 0.10 | 0.11 |
Gross Margin | 45.32% | 45.25% | 53.40% | 58.27% | 56.17% | 73.52% |
Operating Margin | 12.39% | 10.81% | 9.23% | 6.55% | 2.76% | 3.68% |
Profit Margin | 20.10% | 17.65% | 9.54% | 4.58% | -9.37% | 1.43% |
Free Cash Flow Margin | 12.06% | 11.69% | 14.26% | 9.31% | 7.36% | 7.62% |
EBITDA | 322.1 | 319.65 | 316.6 | 276.33 | 215.66 | 254.64 |
EBITDA Margin | 16.98% | 14.97% | 12.97% | 10.52% | 6.94% | 8.10% |
D&A For EBITDA | 87.08 | 88.88 | 91.28 | 104.38 | 130.05 | 138.96 |
EBIT | 235.02 | 230.77 | 225.32 | 171.96 | 85.61 | 115.68 |
EBIT Margin | 12.39% | 10.81% | 9.23% | 6.55% | 2.76% | 3.68% |
Effective Tax Rate | 8.08% | 6.65% | 14.51% | 27.20% | - | 37.38% |
Revenue as Reported | 1,897 | 2,135 | 2,441 | 2,626 | 3,108 | 3,145 |